Nov 4, 4:08 PM ET
Veracyte reported third-quarter 2026 total revenue of $151.8 million, up 15% from a year earlier, and GAAP net income of $31.5 million, or $0.38 per diluted share. The company lowered its 2026 testing revenue guidance to $571 million to $573 million from $576 million to $582 million, and cut the top of its total revenue range to $590 million to $593 million from $590 million to $596 million. The board also authorized a share repurchase program of up to $100 million over 12 months.
- Q3 2026 total revenue $151.8 million, up 15%; Decipher Prostate $92.3 million and Afirma $51.5 million
- GAAP diluted EPS $0.38 vs. $0.24 a year earlier; non-GAAP diluted EPS $0.51, flat year over year
- 2026 testing revenue guidance cut to $571 million to $573 million from $576 million to $582 million
- Board authorized buyback of up to $100 million over 12 months; cash and short-term investments were $370.5 million at September 30, 2026
Read the filing on SEC.gov ↗
Sep 14, 4:07 PM ET
Veracyte, Inc. completed its acquisition of Convergent Genomics on September 14, 2026, through a merger under an agreement signed September 10, 2026, adding the UroAmp urine tumor DNA platform for bladder cancer. The filing states the company did not update its previously provided 2026 adjusted EBITDA guidance, which already contemplated Convergent's operating expenses, and no financial results for Convergent were disclosed.
- Upfront cash consideration of $150 million, subject to customary purchase price adjustments
- Up to $30 million in additional cash tied to UroAmp publication and reimbursement milestones
- Merger agreement dated September 10, 2026; closing completed September 14, 2026
- Veracyte expects to commercialize its first UroAmp-based test in late 2028, subject to reimbursement timelines
Read the filing on SEC.gov ↗
Jul 30, 4:18 PM ET
Veracyte reported second-quarter 2026 total revenue of $150.3 million, up 15% from a year earlier, and GAAP net income of $25.5 million, or $0.31 per diluted share, compared with a net loss of $980,000 a year earlier. The company raised its 2026 total revenue guidance to $590 million to $596 million, which signals stronger expected growth for shareholders.
- Total revenue rose 15% to $150.3 million; testing revenue rose 19% to $145.7 million
- GAAP net income was $25.5 million, or $0.31 per diluted share, versus a net loss of $980,000 in Q2 2025
- 2026 total revenue guidance raised to $590 million to $596 million from $582 million to $592 million
- Cash, cash equivalents and short-term investments totaled $485.2 million as of June 30, 2026
Read the filing on SEC.gov ↗
Jun 11, 4:32 PM ET
At its June 10, 2026 annual meeting, Veracyte stockholders approved an amendment adding 3,500,000 shares to the 2023 Equity Incentive Plan, and elected all nine director nominees. Stockholders also ratified Ernst & Young LLP as the independent auditor for 2026 and approved executive compensation on an advisory basis. The larger share reserve gives the company more room to grant equity awards, and the plan vote drew 21,060,296 votes against.
- Stockholders approved adding 3,500,000 shares to the 2023 Equity Incentive Plan: 52,059,077 for, 21,060,296 against.
- All nine director nominees, including Eliav Barr and Brent Shafer, were elected to serve until the 2027 annual meeting.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- The Board approved the plan amendment on April 8, 2026, subject to stockholder approval.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.